Halozyme Therapeutics (HALO) net assets (shareholders' equity)

Net assets · fiscal 2025
$48.81M

Halozyme Therapeutics (HALO) had net assets of $48.81M at the end of fiscal 2025 (December 31, 2025). That is 86.6% lower than the $363.82M of fiscal 2024. Figures as of 18 Nov 2026, 23:55 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$48.81M
Change on fiscal 2024
−86.6%
Growth, 5 years
−20.2% a year
Growth, 10 years
+1.3% a year
Highest on record
$363.82Mfiscal 2024
Lowest on record
-$32.48Mfiscal 2016
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Halozyme Therapeutics net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets shrank at a compound 20.2% a year; over ten years the rate was 1.3% a year. Across the 17 fiscal years on record (2009–2025), the highest was $363.82M in fiscal 2024 and the lowest -$32.48M in fiscal 2016.

History · 17 fiscal years

Net assets by fiscal year

Halozyme Therapeutics net assets (shareholders' equity), year by year

Halozyme Therapeutics (HALO) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$48.81M 86.6% down
2024$363.82M 334.1% up
2023$83.81M 50.6% down
2022$169.80M 13.8% down
2021$196.95M 30.4% up
2020$151.05M 64.6% up
2019$91.77M 63.1% down
2018$248.89M 19.4% up
2017$208.37M—
2016-$32.48M 175.5% down
2015$43.00M 4.0% up
2014$41.35M—
2013-$19.99M 140.9% down
2012$48.86M 348.2% up
2011$10.90M 46.4% down
2010$20.35M 194.8% up
2009$6.90M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Halozyme Therapeutics and comparable companies
CompanyNet assetsFiscal year
Fresenius Medical Care FMS€13.31B2025
Kymera Therapeutics KYMR$1.58B2025
DaVita DVA-$651.08M2025
Halozyme Therapeutics HALO$48.81M2025
Universal Health Services UHS$7.28B2025
Repligen RGEN$2.11B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on HALO

Halozyme Therapeutics, figure by figure

Halozyme Therapeutics (HALO) overview: price, valuation and scorecardAll health care companies by market value

Halozyme Therapeutics net assets (shareholders' equity): questions and answers

What are Halozyme Therapeutics's net assets?

Halozyme Therapeutics (HALO) had net assets of $48.81M at the end of fiscal 2025 (December 31, 2025). That is 86.6% lower than the $363.82M of fiscal 2024.

What is the growth rate of Halozyme Therapeutics's net assets?

Over the five fiscal years to 2025 net assets shrank at a compound 20.2% a year; over ten years the rate was 1.3% a year.

What are the highest and lowest net assets figures on record for Halozyme Therapeutics?

Across the 17 fiscal years on record (2009–2025), the highest was $363.82M in fiscal 2024 and the lowest -$32.48M in fiscal 2016.

How is Halozyme Therapeutics's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Halozyme Therapeutics it is on record here for 17 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Halozyme Therapeutics (HALO) net assets (shareholders' equity)”, data as of 18 November 2026. https://funkfolio.com/stock/HALO/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.